MedTrace Logo

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

NCT04588298 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2025-01-24

Study results available
· View outcomes & findings →

Summary

This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with primary breast cancer

Conditions

Interventions

DRUG

AZD9833

AZD9833 tablets will be administered orally.

Sponsors & Collaborators

Principal Investigators

  • John Robertson · Graduate Entry Medicine & Health School, University of Nottingham, Royal Derby Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2023-06-19
Completion
2023-06-19

Countries

  • Georgia
  • Mexico
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04588298 on ClinicalTrials.gov